Original language | English |
---|---|
DOIs | |
Publication status | Published - 10 Oct 2023 |
Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study
Jason Aldred*, Eric Freire-Alvarez, Alexander V. Amelin, Angelo Antonini, Bruno Bergmans, Filip Bergquist, Manon Bouchard, Kumar Budur, Camille Carroll, K. Ray Chaudhuri, Susan R. Criswell, Erik H. Danielsen, Florin Gandor, Jia Jia, Thomas E. Kimber, Hideki Mochizuki, Weining Z. Robieson, Amy M. Spiegel, David G. Standaert, Saritha Talapala
*Corresponding author for this work
- Selkirk Neurology and Inland Northwest Research
- Hospital General Universitario de Elche
- Pavlov First State Medical University of St. Petersburg
- University of Padua
- General Hospital St. Jan
- Ghent University
- University of Gothenburg
- Clinique Neuro-Lévis
- AbbVie
- King's College London
- Washington University St. Louis
- Aarhus University
- Movement Disorders Hospital
- Otto von Guericke University Magdeburg
- Royal Adelaide Hospital
- University of Adelaide
- Osaka University
- University of Alabama at Birmingham
- University of Sydney
- Westmead Hospital
Research output: Other contribution › peer-review
13
Downloads
(Pure)